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INTRODUCTION
Prediction of chemotherapy response before application
to the patients may improve response to chemotherapy and
reduce toxicity and the cost of care, providing tailored treat-
ment to individual patients. Chemosensitivity assays refer
to any in vitro laboratory analysis that are performed specif-
ically to evaluate whether tumor growth is inhibited by a
known chemotherapy drug (1). Ideal in vitro chemosensitivi-
ty testing should be reproducible, feasible with small amount
of tissue, and the result should be available fast with high
accuracy in predicting clinical response. Various chemosen-
sitivity and resistance assays have been developed (2-4) but
few have gained enough evidence to be utilized in clinical
practice due to poor success rate, ambiguous criteria for defin-
ing in vitro sensitivity, prolonged turnaround time and lack
of large, randomized trials comparing assay-guided therapy
versus empirical therapy (5). American Society of Clinical
Oncology Technology Assessment does not support use of
any chemotherapy sensitivity and resistance assays for oncol-
ogy practice (1). 
Adenosine triphosphate (ATP)-based chemosensitivity test
uses intracellular ATP level, to detect viability of cells under
various concentrations of chemotherapeutic agents (6). It was
reported to be more reproducible, feasible with smaller amount
of tissue required and clinical application has been reported
in melanoma, ovarian, and breast cancers (7-10), some stud-
ies showing correlation of in vitro response with clinical res-
ponse and survival. However, few studies used predefined
specific criteria for defining in vitro chemosensitivity, using
clinical response in prospective clinical trials as a reference
standard. 
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Individualized Tumor Response Testing for Prediction of Response to
Paclitaxel and Cisplatin Chemotherapy in Patients with Advanced
Gastric Cancer
The purpose of our study was to determine the most accurate analytic method to
define in vitro chemosensitivity, using clinical response as reference standard in
prospective clinical trial, and to assess accuracy of adenosine triphosphate-based
chemotherapy response assay (ATP-CRA). Forty-eight patients with chemo-naïve,
histologically confirmed, locally advanced or metastatic gastric cancer were enrolled
for the study and were treated with combination chemotherapy of paclitaxel 175
mg/m
2 and cisplatin 75 mg/m
2 for maximum of six cycles after obtaining specimen
for ATP-CRA. We performed the receiver operator characteristic curve analysis
using patient responses by WHO criteria and ATP-CRA results to define the method
with the highest accuracy. Median progression free survival was 4.2 months (95%
confidence interval [CI]: 3.4-5.0) and median overall survival was 11.8 months (95%
CI: 9.7-13.8) for all enrolled patients. Chemosensitivity index method yielded high-
est accuracy of 77.8% by ROC curve analysis, and the specificity, sensitivity, posi-
tive and negative predictive values were 95.7%, 46.2%, 85.7%, and 75.9%. In vitro
chemosensitive group showed higher response rate (85.7% vs. 24.1%) (P=0.005)
compared to chemoresistant group. ATP-CRA could predict clinical response to
paclitaxel and cisplatin chemotherapy with high accuracy in advanced gastric can-
cer patients. Our study supports the use of ATP-CRA in further validation studies. 
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We used a modified method of ATP-based chemotherapy
response assay (ATP-CRA) which adopted ultra-low attach-
ment culture plates to inhibit the growth of normal cells to
increase feasibility of the test using smaller amount of tissue
and to shorten turnaround time (11, 12). This modified ATP-
CRA has been tested and validated in various cancers includ-
ing ovarian, breast and lung cancers (12-14), however, spe-
cific in vitro criteria defining chemosensitivity was not defined
in prospective clinical trial and heterogenous methods were
used in each study. The purpose of our study was to deter-
mine the most accurate analytic method to define in vitro
chemosensitivity, using clinical response as reference standard
in prospective clinical trial, and to assess accuracy of ATP-
CRA using the method defined. We also set out to test the
hypothesis that in vitro chemosensitivity could predict clin-
ical outcomes in terms of response rate, progression free sur-
vival (PFS) and overall survival (OS) in advanced gastric cancer. 
MATERIALS AND METHODS
Study design
This trial was designed to define accuracy of ATP-CRA test
in gastric cancer patients receiving paclitaxel and cisplatin
chemotherapy, by comparing clinical response and ATP-CRA
results in prospective, multi-center clinical trial. Primary end
point was to assess accuracy of ATP-CRA results, and secondary
endpoint was to find best method of defining in vitro chemo-
sensitivity. Sample size was calculated to show sensitivity or
specificity of ATP-CRA was more than 80%, to be 62 (a=0.05,
d=0.10). Considering 25% technical failure rate and 15%
clinical drop out rate, total of 90 patients were to be enrolled. 
Patients
Patients with chemotherapy-naïve, histologically or cyto-
logically proven, metastatic or locally advanced gastric can-
cer not amenable to curative resection were enrolled for the
study. Patient had to have at least 50 mg (endoscopic biop-
sy) or 250 mg (surgical biopsy) of tumor obtained, or at least
500 mL of ascites or pleural effusion, with more than 30%
tumor cells to be included in the trial. Other inclusion cri-
teria included age between 18-70, Karnofsky performance
status: 60-100, bidimensionally measurable disease with more
than 20 mm in computed tomography (CT) scan or 10 mm
in radiography or physical examination and at least 12 weeks
of life expectancy. Adjuvant chemotherapy given 6 months
prior to enrollment was allowed and radiotherapy was allowed
if the portal was outside of the measurable disease, with more
than 4 weeks interval before enrollment. Patients who had
active central nervous system metastasis, active infection, or
other serious illness or medical conditions were excluded.
Patients with less than 30% of tumor cells in malignant effu-
sion were excluded from the study. This study was approved
by local institutional review board (IRB) and all participants
signed informed consent before enrollment. IRB approval
numbers of participating centers are as follows; Seoul Nation-
al University Bundang Hospital H-0306/104-009, Korea
University Anam Hospital AN0328-001, Yeungnam Uni-
versity Medical Center 04-31-10, Seoul National Universi-
ty Boramae Hospital 06-2003-07, Seoul Paik Hospital 05-
04-42, Korea Cancer Center Hospital 04-22(4), Seoul Nation-
al University Hospital H-0306/104-009. 
ATP-based chemotherapy response assay
After obtaining informed consent for the study, tumor tis-
sues were obtained by endoscopic biopsy, paracentesis of ascites,
or excisional biopsy. Tumors were kept in transport media,
containing Hank’s balanced salt solution (HBSS, Gibco, Rock-
ville, MD, USA), containing 100 IU/mL penicillin, 100 mg/
mL streptomycin, 100 mg/mL gentamicin and 2.5 mg/mL am-
photericin B and 5% fetal bovine serum, and transported to
central laboratory within 24 hr of procedure. Tumor cells
were separated by previously described method (11). Briefly,
tissues were washed, quantified, minced and then white blood
cells and red blood cells were removed using Ficoll gradient
centrifugation at 400 g for 15 min and using magnetic bead
containing anti-CD45 antibody (Miltenyi Biotech, Auburn,
CA, USA). Tumor cells were diluted and seeded in triplicate
to a 96-well ultra-low attachment plate, at 2,000-20,000 cells/
well. 100 mL of paclitaxel and cisplatin were added to the seed-
ed cell cultures at ×5, 1, 0.5, 0.2, 0.1 times the individual
test drug concentrations (2.5 mg/mL for cisplatin, 3 mg/mL
for paclitaxel) determined by previous method (15, 16), and
incubated for 48 hr in a CO2 incubator. ATP in the cell lysates
of treated and untreated control was measured using flash
type luminescence measurements (Roche, Mannheim, Ger-
many), and the inhibition rate was determined as the rate of
ATP luminescence reduction in the treated group compared
with the untreated control. 
Assessment of clinical and in vitro response
After obtaining tumor tissue, patients received combina-
tion chemotherapy consisting of paclitaxel 175 mg/m2 and
cisplatin 75 mg/m2, on day 1 every 3 weeks for a maximum
of 6 cycles. Tumor response was assessed by WHO criteria
(17), using CT scan taken every 2 cycles. Both laboratory tech-
nicians and physicians were blinded to ATP-CRA results or
clinical results. The chemosensitivity was assessed using 1)
chemosensitivity index (CI) method, CI calculated by adding
the percentage of tumor growth inhibition at each drug con-
centration tested (CI=[100×# concentration tested]-SUM
[% cell suppression at given concentrations among 0.1×-5
×]) (6); 2) comparison of in vitro area under the curve (AUC)
at IC50, drug concentration that achieve 50% growth inhibi-686 J.H. Kim, K.-W. Lee, Y.H. Kim, et al.
tion in vitro, vs. clinical AUC (18, 19); 3) single concentra-
tion arbitrary criteria, which uses cut-off value of in vitro inhibi-
tion rate determined by Fisher’s exact test, which discrimi-
nates clinical responders and non-responders (20); and 4) using
mean value of growth inhibition rate using patient database
(21). Patients were considered to be chemo-sensitive if they
were sensitive to either one of the two drugs, defined by cut
off values determined as above. 
Statistical considerations
Receiver operating characteristic (ROC) curve analysis and
Fisher’s exact test were performed to select analytic method
with highest accuracy. By the method chosen, 2×2 table was
constructed yielding sensitivity, specificity, positive and neg-
ative predictive value, and accuracy was calculated as propor-
tion of true positive and true negative patients out of whole
patients. 
Survival curves were constructed using the Kaplan-Meier
method. The log-rank test was used to compare survival pro-
babilities between in vitro responders and non-responders.
All statistical calculations were carried out by independent
statisticians at CMIC Korea, Ltd., using SAS 8.1 (SAS Insti-
tute, Cary, NC, USA) and the SPSS Windows program ver-
sion 15 (SPSS, Chicago, IL, USA). P values <0.05 were con-
sidered statistically significant.
RESULTS
Patient characteristics
From September 2003 to January 2006, a total of 71 pati-
ents signed informed consent and underwent biopsy from
seven centers. Of the 71 patients, 23 were deemed ineligi-
ble due to not enough tumor cells (n=10), bacterial contam-
ination (n=3), violation of enrollment criteria (n=6), and not
receiving planned treatment (n=4), rendering 48 patients
enrolled. Majority of specimens were endoscopic biopsies of
primary tumor (46 out of 48) and remaining two were ob-
tained from excisional biopsy and ascites. The study was orig-
inally designed to enroll 62 evaluable patients, but the trial
was terminated and analyzed after enrolling 48 patients due
to poor patient accrual.
The median age of the patients were 57 yr (range, 31-70)
and other clinical characteristics are summarized in Table 1.
No patients had received adjuvant chemotherapy or radiother-
Characteristics (n=48)
Age (yr)
Median 57
Range (31-70)
Sex
Male 39
Female 9
Karnofsky performance status
80-100 39
60-70 9
Stage
Locally advanced 17
Metastatic 31
Sampling site
Primary tumor  46
Ascites/lymph node 1/1
Table 1. Patient characteristics
*Mean=29.0521, SD=18.8637; 
�
Mean=29.3019, SD=20.2982.
PPV, positive predictive value; NPV, negative predictive value.
Method, cut off Specificity Sensitivity PPV NPV Accuracy No.
Table 2. Accuracy, sensitivity, specificity, positive predictive value, and negative predictive value according to the four methods of in
vitro chemosensitivity assessment
Chemosensitivity index method
1×+5×, 49.9 95.65 46.15 85.71 75.86 77.78  36
1×+5×, 52.3 91.30  53.85 77.78 77.78 77.78 36
0.2×+1×+5×, 99     95.65 15.38 66.67 66.67 66.67 36
Single concentration arbitrary criteria
cis1× or tax1×, 52.7 86.96 46.15 66.67 74.07 72.22 36
cis5× or tax5×, 99.7 90.48 30.77 66.67 67.86 67.65 34
cis5× or tax1×, 92.4 100.00 23.08 100.00 69.70 72.22 36
cis1×+tax1×, 81.7 82.61 46.15 60.00 73.08 69.44 36
cis5×+tax5×, 187.4 95.24 30.77 80.00 68.97 70.59 34
Comparison of in vitro AUC at IC50 vs. 77.78 33.33 42.86 70.00 70.37 27
clinical AUC, in vitro ≤in vivo, on/off
Using mean value of growth inhibition rate using patient database
Mean+2.0 SD (cisplatin 1×* or paclitaxel 1×
� ), 95.65  23.08 68.75 75.00 69.44 36
Cisplatin 66.8/paclitaxel 69.9ATP-based Chemosensitivity Test in Gastric Cancer 687
apy before enrollment. Of the 48 patients, 11 were inevalu-
able (4 due to inaccurate dose of chemotherapy, 6 were lost
to follow up before response assessment, 1 culture failure and
1 secondary bacterial contamination during the assay) and
36 patients were evaluable for both in vitro and in vivo res-
ponses. 
Response and survival
Thirty-six evaluable patients received total of 152 cycles
of chemotherapy, median number of cycles received was four
(1-6). Among 36 evaluable patients, response rate was 36.1%
with 13 patients achieving partial response, 12 stable disease
and 11 patients with progressive disease. Twenty-seven pati-
ents received second line chemotherapy upon progression.
Median PFS was 4.2 months (95% CI: 3.4-5.0) and median
OS was 11.8 months (95% CI: 9.7-13.8) for all enrolled pati-
ents.
In vitro chemosensitivity results
Of the 48 patients enrolled, 46 specimens yielded chemo-
sensitivity results, with two test failures; one secondary bac-
terial contamination during the assay, one culture failure. The
success rate on the intention-to-assay basis was 75.4% (46 of
61, excluding ten patients with violation of enrollment cri-
teria and who did not receive planned treatment). If the sam-
ples met all the inclusion criteria of more than 50 mg (endo-
scopic biopsy) or 250 mg (surgical biopsy), or at least 500 mL
of ascites or pleural effusion, with more than 30% tumor
cells, the success rate was as high as 95.8% (46 of 48 enrolled
patients). Chemosensitivity was determined using four dif-
ferent methods described in the methods and ROC curve
analysis was performed to define the method with highest
accuracy (Table 2). Chemosensitivity index method, which
used ×1.0 and ×5.0 concentrations and cut-off value of
49.9, were chosen as the method with highest accuracy of
77.8% (Table 2, Fig. 1). This method would define a patient
as in vitro sensitive, if the sum of percentage of cell death at
×1.0 and ×5.0 times peak plasma concentrations of either
paclitaxel or cisplatin were below cut-off value of 49.9. 
Using chemosensitivity index method defined above, spe-
cificity of ATP-CRA was 95.7% (95% CI: 77.2-99.9%); sen-
sitivity 46.2% (95% CI: 19.2-74.9%); positive predictive
value 85.7% (95% CI: 42.1-99.6%); and negative predic-
tive value was 75.9% (95% CI: 55.1-89.3%), respectively
(Table 3). Other methods such as chemosensitivity index
method using ×1 and ×5 concentrations, cut off point of
52.3, single concentration and arbitrary criteria at cisplatin
×1 or paclitaxel ×1 concentrations, cut off point of 52.7
yielded accuracy above 70% (Table 2). 
Using the selected chemosensitivity index method and cut-
off point, seven patients were defined as in vitro sensitive (S)
and 29 patients as resistant (R). S group and R group showed
similar baseline characteristics such as age, sex, stage, perfor-
mance, and whether they received second line chemothera-
py (Table 4). S group showed statistically significantly higher
response rate compared to R group (85.7% vs. 24.1%, P=
Fig. 1. Receiver operating characteristic curve of ATP-chemother-
apy response assay using ×1 and ×5 times test drug concen-
trations of paclitaxel and cisplatin. 
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Table 3. Clinical response versus in vitro chemosensitivity defin-
ed by ATP-based chemotherapy response assay, using che-
mosensitivity index method
Parameters
S group
(n=7)
R group
(n=29)
P
Mean age 55.2 (37-69) 53.8 (32-70) 0.755
Sex 0.671
Male 6 24
Female 1 5
Karnofsky score 0.315
80-100 7 24
60-70 0 5
Stage
Locally advanced 2 11 0.501
Metastatic 5 18
Second line chemotherapy 0.456
Given 4 21
Not given 2 6
Table 4. Characteristics of in vitro chemosensitive versus che-
moresistant patients688 J.H. Kim, K.-W. Lee, Y.H. Kim, et al.
0.005). Progression free survival (median: 4.3 vs. 4.5 months,
mean: 5.5 vs. 4.4 months, P=0.60) and overall survival (8.4
vs. 12.3 months, P=0.08) difference did not reach statistical
significance (Fig. 2). 
DISCUSSION
We found that chemosensitivity index method using×1
and ×5 times peak plasma concentration and cut-off value
of 49.9, was the best method of defining in vitro chemosen-
sitivity with accuracy of 77.8%, specificity of 95.7% and sen-
sitivity of 46.2%. Our study also showed that ATP-CRA was
feasible with small amount of tissue, mainly endoscopic biop-
sies, in multicenter setting with success rate of 75.4% (inten-
tion to assay) or 95.8% (enrolled patients), with turnaround
time of less than 7 days. 
Our results compare favorably with others. O’Meara et al.
reported the results of ATP chemosensitivity assay in ovari-
an cancer, with sensitivity and specificity of 68.8%, 74.3%,
accuracy of 70.7% and positive and negative predictive value
of 83% and 56.5%, respectively (22). They also performed
ROC curve analysis to define the most accurate method and
reported criteria to be cell kill of ≥45% at the dose of 0.5
times peak plasma concentration for paclitaxel. Modified ATP-
CRA used in our study has been tested in various cancers in-
cluding ovarian, breast, and lung cancers (12-14), and these
studies also reported similar or higher accuracy, specificity,
sensitivity and positive and negative predictive values. How-
ever, most of the studies have used mixed population of pati-
ents and included heterogeneous treatment, such as first line
and second line chemotherapy or neoadjuvant and metastat-
ic setting, or were not designed prospectively. Most of the
studies with ATP chemosensitivity assays were performed in
ovarian cancer where maximum debulking surgery is routine-
ly performed prior to chemotherapy and cut-off criteria for
in vitro chemosensitivity was determined using progression
free or overall survival, or CA-125 response, instead of clini-
cal response which requires measurable disease (8, 13, 22). 
In vitro sensitive patients (S-group) defined by ATP-CRA
test showed increased responses rate compared to in vitro resis-
tant patients (R-group), more than three times that of R-group
(85.7% vs. 24.1%). Although the response rate was higher
in the S-group, there were no statistically significant differ-
ences in progression free or overall survival in our patients.
S-group showed tendency for shorter overall survival com-
pared to R-group. Our results are in contrast to others report-
ing correlation of in vitro chemosensitivity with progression
free and/or overall survival, where in vitro chemosensitive
patients showed longer survivals (8, 10, 12). Possible expla-
nations of this discrepancy could mainly be due to small num-
ber of patients enrolled, especially small numbers of in vitro
chemosensitive (S) group. Our study could have been under-
powered according to the initial statistical assumptions and
this could lead to failure to distinguish differences in PFS and
OS. Also, since we only used responders in defining in vitro
sensitivity, value of stable disease could not have been taken
into account and patients with non-responding but with sta-
ble disease would have been classified as R-group. Moreover,
in vitro chemosensitivity could be a marker of aggressiveness,
which may compensate for initial response achieved by che-
motherapy. Our findings warrant further study including
patients with stable disease as responders in defining in vitro
chemosensitivity.
There are several limitations to our study. First, the study
took almost three years to enroll 36 evaluable patients. Many
samples were not enrolled due to bacterial contamination,
inadequate amount of tissue especially during the first few
months. Once the adequate tumor cells were isolated, success
rate of ATP-CRA was 95.8%. Second, the study was origi-
Fig. 2. Progression free and overall survival of in vitro sensitive versus in vitro resistant patients. (A) Progression free survival. (B) Overall
survival.
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nally designed to enroll 62 evaluable patients, to show sensi-
tivity or specificity of ATP-CRA was more than 80% with
type 1 error (a) of 0.05. We had to terminate our study early
due to very poor accrual of patients, and it resulted in inad-
equate power to test the accuracy as planned initially. The
type one error would be 0.067 with 36 evaluable patients,
instead of 0.05 with planned 62 evaluable patients. Third,
because the test accuracy was calculated using the criteria
defined by ROC curve analysis, our study result needs vali-
dation in an independent cohort. We are currently enrolling
patients with lung cancer, using the same paclitaxel plus cis-
platin regimen, and expect to validate this method in this
independent cohort. Fourth, the clinical response was evalu-
ated in the participating centers by the investigators who
were blind to the in vitro chemosensitivity results but there
was no independent review of response evaluation, which
may have been subject to biases. 
Despite limitations, our study is one of the few attempts
to define criteria for in vitro chemosensitivity using clinical
response in a prospectively designed trial as reference stan-
dard. We enrolled homogenous population of chemo-naïve
patients and used homogenous treatment to minimize other
variables that could affect chemosensitivity. 
Positive and negative predictive value of a diagnostic test
depends strongly on the frequency of event, in this case, res-
ponse rate. Even diagnostic test with 95% sensitivity and
specificity would yield very low positive and negative pre-
dictive values if applied to a low prevalence event, whereas
test with high specificity test would yield high negative pre-
dictive value in low prevalence event (23). Considering this
statistical assumption, specificity of more than 95% but rather
low sensitivity of 46.2% of our study support the use of ATP-
CRA in selecting chemotherapeutic agent which would not
benefit patients, in cancers with low response rate where cyto-
toxic chemotherapies benefit only selected patients. Most use-
ful application of ATP-CRA would be for selecting adjuvant
regimen, when chemosensitivity only can be assessed many
years later in terms of disease free survival and selection of
optimal chemotherapeutic agents could increase cure rate. 
In conclusion, ATP-CRA can predict clinical response to
paclitaxel and cisplatin chemotherapy with high success rate
and accuracy in advanced gastric cancer patients. The higher
response rate shown in chemosensitive group supports the
use of ATP-CRA in further validation studies and assay-guid-
ed clinical trials. 
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